|4.||Sarcoma (Soft Tissue Sarcoma)
|1.||Debus, Jürgen: 21 articles (07/2015 - 01/2002)|
|2.||Hornicek, Francis J: 15 articles (12/2015 - 02/2002)|
|3.||Jäkel, Oliver: 12 articles (07/2015 - 05/2002)|
|4.||Duan, Zhenfeng: 12 articles (05/2015 - 06/2009)|
|5.||Choy, Edwin: 11 articles (05/2015 - 06/2009)|
|6.||Leithner, Andreas: 10 articles (01/2015 - 02/2011)|
|7.||Schulz-Ertner, Daniela: 10 articles (07/2011 - 01/2002)|
|8.||Nikoghosyan, Anna: 10 articles (07/2011 - 09/2003)|
|9.||Schwab, Joseph H: 9 articles (12/2015 - 03/2009)|
|10.||Nielsen, G Petur: 9 articles (12/2015 - 09/2009)|
10/01/2011 - "Given the high cost of proton facilities and improved techniques for other forms of radiation therapy, this article evaluates whether proton therapy is still superior to other radiation techniques in the treatment of chordomas."
08/01/2006 - "To assess the efficacy of definitive treatment of sacral chordoma by high-dose proton/photon-beam radiation therapy alone or combined with surgery. "
06/01/2014 - "Chordoma management is more widely studied with en bloc resection and adjuvant proton-beam therapy demonstrating improved progression-free survival and overall survival. "
04/01/2012 - "Multimodal surgery and proton therapy thus improved the chordoma treatment. "
01/01/2010 - "Proton therapy is the gold standard in the treatment of skull base chordomas. "
11/01/2014 - "Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results."
11/01/2014 - "Carbon ion therapy appears to be a safe and effective treatment for patients with skull base chordoma, resulting in high LC and OS rates."
01/01/2014 - "Data of a Japanese study of patients with unresectable sacral chordoma showed comparable high control rates after hypofractionated carbon ion therapy only. "
01/01/2010 - " aim of this study is to find out, whether the biological advantages of carbon ion therapy can also be clinically confirmed and translated into the better local control rates in the treatment of skull base chordomas. "
07/01/2015 - "High-dose photon/carbon ion beam radiation therapy is safe and, especially for primary sacral chordomas, highly effective. "
|3.||Sirolimus (Rapamycin)FDA Link
03/15/2009 - "We also tested the efficacy of the mTOR inhibitor rapamycin on signaling and growth of chordoma cell lines. "
03/15/2009 - "In this study, we investigated whether aberrant TSC/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is associated with sporadic chordomas. "
07/01/2013 - "Rapamycin was identified as an inhibitor of chordoma cell proliferation. "
11/01/2009 - "Since July 2007, 10 progressive advanced chordoma patients with secondary resistance to IM, and biochemical and/or immunohistochemical evidence of upstream and/or downstream mTOR effector activation, started IM (400 mg/day) plus sirolimus (2 mg/day) on a named basis. "
11/01/2009 - "The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma. "
|4.||Brachyury protein (Brachyury)IBA
09/01/2015 - "In conclusion, the results of the present study demonstrated that the expression of Brachyury offers a sensitive marker, but not a risk factor, for skull base chordomas, and radical surgery is recommended."
11/01/2014 - "Several studies demonstrated brachyury expression (T; 6q27) as a possible candidate gene in the oncogenesis of chordomas (e.g. "
11/01/2012 - "Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. "
10/01/2011 - "The authors propose that Brachyury is an attractive therapeutic target in chordoma and that JHC7 will serve as a clinically relevant model for the study of this disease."
08/01/2010 - "Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases."
06/01/1997 - "The expression of CK8 and CK19, observed in all of the chordoma and notochord specimens, was thus considered to be maintained throughout the neoplastic transformation, although some aberrant CK expressions (CK7, CK18, and keratin-903) also occurred in the chordoma specimens examined in this study."
05/01/2010 - "Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma'. "
04/01/2009 - "Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma."
11/01/2001 - "Cytokeratin immunophenotyping of an unusual cervical vertebral chordoma with extensive chondroid foci and perilaryngeal recurrence: a case report with review of the literature."
02/01/1998 - "Chordomas were consistently positive for keratin cocktail AE1/AE3, and for the individual keratins K8 and K19, and nearly always positive for K5, but they showed negative or only sporadic reactivity for K7 and K20. "
|6.||Mucin-1 (CA 15-3 Antigen)IBA
12/01/2008 - "Positivity for both epithelial membrane antigen and AE1/AE3 had a sensitivity of 90% and a specificity of 100% for detecting chordoma in this study. "
05/01/1998 - "Thus, positive staining with epithelial membrane antigen and the identification of a large number of rough endoplasmic reticulum-mitochondrial complexes are suggestive of metastatic chordoma. "
09/01/1987 - "Demonstration of cytokeratins and an epithelial membrane antigen in chondroid chordoma."
11/01/1985 - "Demonstration of cytokeratins and an epithelial membrane antigen in chordomas and human fetal notochord."
01/01/1994 - "The immunohistochemical staining pattern (cytokeratin negative, epithelial membrane antigen (EMA) negative) can be helpful in distinguishing it from chordoma with chondroid differentiation (cytokeratin positive, EMA positive). "
01/01/1994 - "Chondroid chordomas were stained for vimentin with moderate intensity whereas typical chordomas were only slightly stained. "
09/01/1991 - "The five chondroid chordomas exhibited the following pattern: EMA 0%, AE 1/3 0%, DPK 0%, vimentin 100%, S100 100%, NSE 100%, CEA 0%, and HMB-45 0%. "
01/01/1994 - "Vimentin and S-100 were positive in more than 95% of both classic and chondroid chordomas and chondrosarcomas. "
01/01/1993 - "In these cases, the expression of S-100-protein, vimentin and CEA by the chordoma cells and the typical electron microscopic features of chordomas are helpful for the differential diagnosis. "
06/01/2010 - "Chordoma cell lines grew well in 3D culture systems and formed acini-like spheroids and retained the expression of vimentin and cytokeratin. "
|8.||S100 Proteins (S 100 Protein)IBA
11/15/1993 - "Forty-four percent of classic and 85% of chondroid chordomas were positive for S-100 protein. "
12/01/1992 - "In contrast, the remaining three cases without histologic evidence of chordoma differentiation did not stain for CK or EMA, but they did stain for S-100 protein (three of three cases) and VIM (three of three cases). "
05/01/1997 - "Immunocytochemistry with positivity for S-100 protein and cytokeratins was an essential adjunct in the cytologic diagnosis of chordoma and helped in distinguishing it from other chondrogenic tumors. "
12/01/1992 - "Similarly, the conventional chordoma components of these same 13 neoplasms stained for CK (12 of 12 cases), EMA (13 of 13 cases), VIM (12 of 12 cases), S-100 protein (nine of 12 cases), and CEA (two of nine cases). "
02/15/1988 - "Reticulum histiocytic cells of eosinophilic granulomas and chordoma cells were positive for S-100 protein. "
|9.||Biological Markers (Surrogate Marker)IBA
09/01/2009 - "A major obstacle in the effective treatment of chordoma is that there are no identifiable biomarkers capable of predicting prognosis. "
09/15/2015 - "Overall, our work offers a valuable new tool for chordoma studies including the development of novel biomarkers and molecular targeting strategies."
01/01/2013 - "The aim of this study was to explore whether DNA methylation, a well known epigenetic marker, may play a role in chordoma development and if hypermethylation of specific CpG islands may serve as potential biomarkers correlated with SNP analyses in chordoma. "
06/01/2012 - "The marked trend of the investigated biomarkers of this study may build a starting point for further investigations as molecular targets for future adjuvant therapies in chordomas. "
05/01/2015 - "This finding sheds light on unraveling the pathophysiology of chordoma recurrence and on exploring more effective prognostic biomarkers and targeted therapies against this devastating disease."
11/01/2014 - "The current study was conducted to evaluate the long-term results of irradiation with carbon ions in a raster scanning technique in patients with skull base chordomas. "
08/21/2003 - "Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions."
11/01/2010 - "A 27-year-old woman diagnosed for a skull-base chordoma and whose pregnancy was found during the course of radiotherapy with accelerated carbon ions. "
07/01/2014 - "Reirradiation with carbon ions is a safe and effective method in patients with relapsed chordoma and chondrosarcoma of the skull base."
07/01/2014 - "To evaluate the safety and efficacy of reirradiation with carbon ions in patients with relapse of skull base chordoma and chondrosarcoma. "
03/01/2015 - "Adjuvant high-dose stereotactic fractionated radiotherapy (HS-FSRT) significantly improved 5 year PFS in craniocervical chordoma patients (70%, n=13) as compared to standard dose radiation therapy (20%, n=16; p-value=0.03). "
09/01/2013 - "Given the implications of pAKT positivity, RTK inhibitors might be efficacious, and drugs that inhibit AKT, alone or in combination with radiotherapy, could be an effective treatment for patients with refractory chordomas. "
01/01/2013 - "Though locally aggressive, chordomas are effectively treated with resection and postoperative radiotherapy."
04/01/1969 - "[Sacral chordoma: long remission after local radiotherapy]."
01/01/2010 - "The study has demonstrated effectiveness of radiotherapy of skull base chordomas."
|2.||Drug Therapy (Chemotherapy)
01/01/2013 - "A review of the medical literature is performed, using standard search engines and identifying articles related to skull base chordomas, surgery, radiation therapy, chemotherapy, molecular genetics, and prospective trials. "
08/01/1993 - "A trial of reasonably aggressive chemotherapy is warranted in patients with metastatic dedifferentiated chordoma. "
01/01/2015 - "Our results contribute to the understanding of the expression of RTKs in skull base chordomas and support the development of targeted therapies that inhibit RTKs, which may have a synergistic effect for chemotherapy in patients. "
01/01/2015 - "Treatment options are mainly restricted to surgical excision, since chordomas are largely resistant to conventional ionising radiation and chemotherapy. "
01/01/2015 - "Management and treatment of chordomas are difficult as they are resistant to conventional chemotherapy; therefore, they are mainly treated with surgery and radiation therapy. "
10/01/1997 - "[Stereotactic brachytherapy for clival chordoma]."
10/01/1997 - "Brachytherapy is believed to be effective for clival chordomas, but technical difficulties exist in stereotactic insertion of catheters into the clivus. "
01/01/1998 - "External radiotherapy plus intracavitary brachytherapy for recurrent chordoma of the nasopharynx."
10/01/1997 - "Our results suggested that stereotactic brachytherapy is potentially useful for the control of clival chordomas and that computer-guided transnasal stereotactic insertion enables implantation of catheters less invasively and more accurately than does X-ray fluoroscopic guidance alone."
03/01/1988 - "Using new 125I brachytherapy techniques, we were able to deliver safely a tumor volume dose of 16,000 rads to a previous irradiated, large, recurrent sacral chordoma by means of the intraoperative interstitial implantation of 229 low activity 125I seeds and 40,000 rads to a previously irradiated, small, recurrent clival chordoma by means of the transnasal needle implantation of two high activity 125I seeds. "
|4.||Heterologous Transplantation (Xenotransplantation)
04/01/2012 - "In this study, the authors aimed to develop a primary chordoma xenograft model. "
09/01/2014 - "This is the first report on xenografts generated from U-CH2b cells in which a low tumorigenicity was discovered despite evidence of chordoma-like characteristics in vitro. "
09/01/2014 - "Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines."
02/01/2014 - "The recurrent chordoma and the derived human chordoma xenograft were compared by histology, immunohistochemistry, and phospho-specific immunohistochemistry. "
02/01/2014 - "The authors sought to establish and characterize a primary xenograft model for chordoma that faithfully recapitulates the molecular features of human chordoma. "
|5.||Molecular Targeted Therapy
01/01/2005 - "In spite of the scarce knowledge on the genetics and molecular biology of chordoma, recent initiation of clinical trials using molecular-targeted therapy, should validate new molecular targets and predict the efficacy of a given therapy. "
01/01/2012 - "Genetic and molecular studies on oncogenesis of chordomas are still limited, but they represent the basis for the development of molecular targeted therapies. "
07/01/2015 - "Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses."
06/01/2015 - "Our case report highlights two cases of sacral chordoma with locally recurrent and widespread metastatic disease, stable on molecular targeted therapy. "
01/01/2011 - "The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients."